TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39724020

Group type: EXPERIMENTAL
Intervention: Active PBMT (LED therapy: DUO 240 [red at 660nm and near-infrared at 840nm] and BIOFLEX LDR-100 laser probe (660nm red light) and LD1-200 laser probe (825nm near-infrared light))
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (non-effective doses of LED array and laser therapy)
Number of subjects: 180
Study: 39724200

Group type: EXPERIMENTAL
Intervention: Microdrops of 1.67% phenylephrine and 0.33% tropicamide
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard drops of the diluted mixture
Number of subjects: 83
Study: 39724376

Group type: EXPERIMENTAL
Intervention: IMB-NIV program (6-week intervention combining in-person and telecare sessions)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: IMB-NIV program
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 124
Study: 39724565

Group type: EXPERIMENTAL
Intervention: Nefecon
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 39725004

Group type: EXPERIMENTAL
Intervention: Gamified ABM
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Traditional ABM
Number of subjects: 600

Group type: COMPARATOR
Intervention: Traditional sham ABM
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Gamified ABM and Traditional ABM
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Post-treatment assessments
Number of subjects: 600
Study: 39725051

Group type: EXPERIMENTAL
Intervention: Placebo response induced through saline injection plus verbal suggestion
Number of subjects: 113
Study: 39725418

Group type: EXPERIMENTAL
Intervention: Low-added sugar diet (<5% of kcal from added sugars)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-added sugar diet (≥13% kcal from added sugars)
Number of subjects: 60
Study: 39725423

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: SF-6Dv1
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L and SF-6Dv1
Number of subjects: 313
Study: 39725450

Group type: EXPERIMENTAL
Intervention: Enhanced nutrition package (iron and folic acid, monthly household supply of iodised salt, and micronutrient-fortified balanced energy protein supplement for undernourished women)
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Enhanced infection management package (genitourinary tract infection screening and treatment, and enhanced deworming)
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Both enhanced nutrition and infection management packages
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2399
Study: 39725465

Group type: EXPERIMENTAL
Intervention: 4-month online group coaching
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not offered coaching)
Number of subjects: 160
Study: 39725584

Group type: EXPERIMENTAL
Intervention: Romi-GemOxD (romidepsin, gemcitabine, oxaliplatin, and dexamethasone)
Number of subjects: 24
Study: 39725764

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Wire localized lymph node biopsy (WLNB)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 208
Study: 39725778

Group type: EXPERIMENTAL
Intervention: ME-344 plus bevacizumab
Number of subjects: 23
Study: 39725795

Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bisoprolol 5-10 mg daily
Number of subjects: 60
Study: 39725891

Group type: EXPERIMENTAL
Intervention: Cognitive assessment using the CPCog protocol including general cognitive functioning, executive functions, and visuo-motor skills.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Supplementary tests covering verbal and nonverbal short-term memory, attention, fatigue, and mental health.
Number of subjects: 100
Study: 39725982

Group type: EXPERIMENTAL
Intervention: SB-VF plus treatment as usual (TAU) (n = 41)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (n = 38)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: SB-VF plus treatment as usual (TAU)
Number of subjects: 172
Study: 39725988

Group type: EXPERIMENTAL
Intervention: Individualized perioperative blood pressure management (maintaining mean arterial pressure and systolic blood pressure at no less than 20% of baseline values)
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Conventional perioperative blood pressure management (maintaining mean arterial pressure at ≥65 mmHg and systolic blood pressure ≥90 mmHg)
Number of subjects: 1896
Study: 39726097

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39726143

Group type: EXPERIMENTAL
Intervention: Stay-at-home orders and decreased outdoor trigger exposure
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Access to medical care during the pandemic
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Indoor triggers like secondhand smoke
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Opportunities for physical activity
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Caregiver and child mental health
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Continuity of medical care
Number of subjects: 61
Study: 39726674

Group type: EXPERIMENTAL
Intervention: Fumagillin
Number of subjects: 0
Study: 39726877

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: venlafaxine
Number of subjects: 0
Study: 39726942

Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staged complete revascularization (CR)
Number of subjects: 0
Study: 39727027

Group type: EXPERIMENTAL
Intervention: EC-IC bypass surgery with medical therapy
Number of subjects: 324

Group type: COMPARATOR
Intervention: Medical therapy (antiplatelet therapy and stroke risk factor control)
Number of subjects: 324
Study: 39727053

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg single dose)
Number of subjects: 38
Study: 39727196

Group type: EXPERIMENTAL
Intervention: N-acetyltransferase 2 gene (NAT2) slow acetylator status
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (matched for sex, age, BMI, tuberculosis diagnosis)
Number of subjects: 102
Study: 39727210

Group type: EXPERIMENTAL
Intervention: Salsalate (part of TINSAL-T1DN trial)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers (39 measured in TINSAL-T1DN)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 525
Study: 39727283

Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 500 mg TID
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 1000 mg TID
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 1500 mg TID
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 2000 mg TID
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 39727287

Group type: EXPERIMENTAL
Intervention: Virtual Arm Boot Camp (V-ABC)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waitlist control (usual care)
Number of subjects: 73
Study: 39727476

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride Gel
Number of subjects: 0
Study: 39728301

Group type: EXPERIMENTAL
Intervention: Atherosclerotic cardiovascular disease (ASCVD)
Number of subjects: 7704

Group type: EXPERIMENTAL
Intervention: Treated hypercholesterolemia
Number of subjects: 7704

Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 7704

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 7704

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 7704

Group type: EXPERIMENTAL
Intervention: Abnormal thyroid function (ATF)
Number of subjects: 7704

Group type: EXPERIMENTAL
Intervention: Family history of ASCVD
Number of subjects: 7704

Group type: EXPERIMENTAL
Intervention: Lipid values
Number of subjects: 7704
Study: 39728634

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39728639

Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care intervention (Thrive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence Based Quality Improvement (EBQI) meetings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formative Evaluation (FE) research
Number of subjects: 0
Study: 39729067

Group type: EXPERIMENTAL
Intervention: Short-term menopausal hormone therapy (mHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated systolic blood pressure (SBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated diastolic blood pressure (DBP)
Number of subjects: 0
Study: 39729135

Group type: EXPERIMENTAL
Intervention: Short cemented stem THA
Number of subjects: 96
Study: 39729186

Group type: EXPERIMENTAL
Intervention: Power training (PWT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 57
Study: 39729347

Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide-1 Receptor Agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium-Glucose Cotransporter 2 Inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipeptidyl Peptidase-4 Inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 0
Study: 39729390

Group type: EXPERIMENTAL
Intervention: SAMHD1 protein expression in HER2-enriched/HER2+ and basal-like (BL)/ER-/HER2- breast cancer
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: SAMHD1 gene expression
Number of subjects: 564

Group type: COMPARATOR
Intervention: SAMHD1 mRNA levels in responders receiving capecitabine
Number of subjects: 564
Study: 39729440

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation via rectal tube, using a preparation mixed from 7 thawed aliquots (50 mL) from fresh stool of 7 healthy unrelated donors.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard treatment based on oral diosmectite.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation via rectal tube.
Number of subjects: 36
Study: 39729499

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) as first-line therapy
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) as first-line therapy
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 997

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 997

Group type: COMPARATOR
Intervention: Intensive care unit stay
Number of subjects: 997

Group type: COMPARATOR
Intervention: Transfusion events
Number of subjects: 997
Study: 39729677

Group type: EXPERIMENTAL
Intervention: KRAS wild-type (KRASwt) patients
Number of subjects: 378

Group type: COMPARATOR
Intervention: KRAS mutated (KRASm) patients
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumors
Number of subjects: 378

Group type: COMPARATOR
Intervention: KRAS mutated tumors
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: KRAS wild-type PDAC
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Patients considered eligible for early-phase trials
Number of subjects: 378
Study: 39729682

Group type: EXPERIMENTAL
Intervention: HET score
Number of subjects: 1460

Group type: COMPARATOR
Intervention: HEART score
Number of subjects: 1460
Study: 39729872

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove intervention
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Exposure-response analysis with BC
Number of subjects: 3200
Study: 39730000

Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab (anti-PD1 antibody), exemestane (nonsteroidal aromatase inhibitor), and leuprolide (gonadotropin-releasing hormone agonist)
Number of subjects: 15
Study: 39730001

Group type: EXPERIMENTAL
Intervention: GPH (gemcitabine, paricalcitol, hydroxychloroquine)
Number of subjects: 0
Study: 39730078

Group type: EXPERIMENTAL
Intervention: digital cognitive behavioral therapy for insomnia (dCBT-I)
Number of subjects: 300

Group type: COMPARATOR
Intervention: patient education control program
Number of subjects: 300
Study: 39730154

Group type: EXPERIMENTAL
Intervention: Postnatal foot length (FL) measurement cutoff of ≤7.6 cm
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Foot length measurement
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Foot length cutoff of ≤7.6 cm
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Postnatal FL measurement
Number of subjects: 336
Study: 39730195

Group type: EXPERIMENTAL
Intervention: Birth in NICU
Number of subjects: 18847

Group type: COMPARATOR
Intervention: Birth in LNU
Number of subjects: 18847
Study: 39730694

Group type: EXPERIMENTAL
Intervention: Quantitative electroencephalogram (qEEG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-delirium group (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Delirium group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peak value of F3-P3 derivation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age, APACHE II scores, lactate, hospital days
Number of subjects: 60
Study: 39731054

Group type: EXPERIMENTAL
Intervention: Implementation of HIV teams with trained GP ambassadors and expert-led education for GPs (phase 1) and peer-to-peer case feedback (phase 2).
Number of subjects: 132338

Group type: EXPERIMENTAL
Intervention: Implementation of HIV teams (phase 1 and phase 2).
Number of subjects: 132338

Group type: EXPERIMENTAL
Intervention: Implementation of HIV teams.
Number of subjects: 132338
Study: 39731056

Group type: EXPERIMENTAL
Intervention: Internet-based emotion regulation intervention
Number of subjects: 20
Study: 39731060

Group type: EXPERIMENTAL
Intervention: Infant formula containing Bifidobacterium animalis ssp. lactis CP-9
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Infant formula containing Lactobacillus salivarius AP-32
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 180
Study: 39731098

Group type: EXPERIMENTAL
Intervention: iPeer2Peer program (peer mentoring through up to ten 30-min video calls over a 15-week period)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: iPeer2Peer program
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 164
Study: 39731129

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 2365

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2365
Study: 39731298

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) plus methylene blue tracing for sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC)
Number of subjects: 156
Study: 39731636

Group type: EXPERIMENTAL
Intervention: Self-etch (SE) mode
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Selective-enamel-etching (SLE) mode
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (ER) mode
Number of subjects: 25
Study: 39731853

Group type: EXPERIMENTAL
Intervention: MASH patients undergoing bariatric surgery
Number of subjects: 100
Study: 39731908

Group type: EXPERIMENTAL
Intervention: Adoptive Treg therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control reference group
Number of subjects: 10
Study: 39731909

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ; 600 mg, bid) plus palbociclib (200 mg, qd)
Number of subjects: 29
Study: 39732356

Group type: EXPERIMENTAL
Intervention: CDED (2 weeks of EEN followed by CDED+PEN)
Number of subjects: 56

Group type: COMPARATOR
Intervention: EEN (8 weeks of EEN followed by PEN with free diet)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CDED
Number of subjects: 56

Group type: COMPARATOR
Intervention: EEN
Number of subjects: 56
Study: 39732365

Group type: EXPERIMENTAL
Intervention: Neoadjuvant osimertinib (2 cycles of 28 days) followed by surgical resection and 3 years of adjuvant osimertinib
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Neoadjuvant osimertinib
Number of subjects: 25
Study: 39732398

Group type: EXPERIMENTAL
Intervention: MCT (15g) before breakfast, water before lunch and dinner
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MCT (15g) before breakfast and WPI (10g) before lunch and dinner
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (water before meals)
Number of subjects: 21
Study: 39732437

Group type: EXPERIMENTAL
Intervention: Vegan diet (10-day controlled)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Omnivorous diet (10-day controlled, 60% animal protein)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 34
Study: 39732438

Group type: EXPERIMENTAL
Intervention: Psyllium (20g)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Divided doses of inulin (20g in 62.5mL every 45 minutes over 6 hours)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Maltodextrin (20g)
Number of subjects: 17
Study: 39732474

Group type: EXPERIMENTAL
Intervention: Proactive home visits by community health workers (CHWs)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Fixed-site CHW care
Number of subjects: 137
Study: 39732483

Group type: EXPERIMENTAL
Intervention: Functional remission group (patients who achieved functional remission after antipsychotic discontinuation)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Functional non-remission group (patients who did not achieve functional remission after antipsychotic discontinuation)
Number of subjects: 480
Study: 39732493

Group type: EXPERIMENTAL
Intervention: Spontaneous vaginal birth
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Instrumental vaginal birth (IVB)
Number of subjects: 897

Group type: COMPARATOR
Intervention: General population
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Experience of care
Number of subjects: 897
Study: 39732649

Group type: EXPERIMENTAL
Intervention: Once weekly self-collected oral swabs (OS)
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Once-weekly self-collected oral-nasal swab (ONS)
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Nurse collected nasopharyngeal swab (NPS)
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Overall adherence and acceptability of ONS and OS
Number of subjects: 1570

Group type: COMPARATOR
Intervention: Symptomatic only SARS-CoV-2 testing arm
Number of subjects: 1570
Study: 39732657

Group type: EXPERIMENTAL
Intervention: SARC-F questionnaire
Number of subjects: 2455

Group type: EXPERIMENTAL
Intervention: SARC-CalF questionnaire
Number of subjects: 2455

Group type: EXPERIMENTAL
Intervention: Calf circumference
Number of subjects: 2455
Study: 39732696

Group type: EXPERIMENTAL
Intervention: UFH/LMWH + 20 mg rtPA/6 h intravenously
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: UFH + 20 mg rtPA/6 h via USAT
Number of subjects: 210

Group type: COMPARATOR
Intervention: UFH/LMWH
Number of subjects: 210
Study: 39732701

Group type: EXPERIMENTAL
Intervention: mSoCIAL (modified Social Cognition Individualized Activity Lab), 10 weekly sessions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: mSoCIAL (modified Social Cognition Individualized Activity Lab)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 40
Study: 39732703

Group type: EXPERIMENTAL
Intervention: 250 mg AYP-101
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 500 mg AYP-101
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 39732716

Group type: EXPERIMENTAL
Intervention: MRSA nasal swab PCR testing in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 39732915

Group type: EXPERIMENTAL
Intervention: Higher pain experienced during labor
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Lower education level
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Having diabetes
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Presence of obstetric complications
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Artificial rupture of membrane (ARM) and oxytocin induction
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Lower age
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Higher A-LPQ birth pain score
Number of subjects: 813
Study: 39733245

Group type: EXPERIMENTAL
Intervention: Urine-based POC metric of PrEP adherence counseling
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard-of-care counseling
Number of subjects: 46
Study: 39733282

Group type: EXPERIMENTAL
Intervention: Bilateral pudendal nerve blockade
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bilateral normal saline pudendal injections
Number of subjects: 104

Group type: COMPARATOR
Intervention: No pudendal injection
Number of subjects: 104
Study: 39733294

Group type: EXPERIMENTAL
Intervention: p-DCR-FFP (250 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: p-DCR-normal saline
Number of subjects: 10
Study: 39733457

Group type: EXPERIMENTAL
Intervention: AVIAR 2.0 system for robot-assisted PCI
Number of subjects: 20
Study: 39733460

Group type: EXPERIMENTAL
Intervention: Distal Radial Access (DRA)
Number of subjects: 1586
Study: 39733934

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 16
Study: 39734047

Group type: EXPERIMENTAL
Intervention: Sprifermin 100 μg every 6 months (Q6M)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Sprifermin 100 μg every 12 months (Q12M)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Sprifermin 30 μg every 6 months (Q6M)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Sprifermin 30 μg every 12 months (Q12M)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Symptom progressors
Number of subjects: 549
Study: 39734195

Group type: EXPERIMENTAL
Intervention: ReAces occluder
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional occluders
Number of subjects: 30
Study: 39734604

Group type: EXPERIMENTAL
Intervention: Scapular Functional Exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervical Isometric Exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39734708

Group type: EXPERIMENTAL
Intervention: CEA-directed CAR T therapy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Glucocorticoids combined with vedolizumab
Number of subjects: 2